Previous 10 | Next 10 |
The following slide deck was published by Biomea Fusion, Inc. in conjunction with this event. For further details see: Biomea Fusion (BMEA) Investor Presentations - Slideshow
Data demonstrated robust anti-tumor activity of BMF-219 and mechanistic evidence for novel inhibition of menin protein in preclinical models of Diffuse Large B-cell Lymphoma (DLBCL) and multiple myeloma (MM). BMF-219 displayed single agent potency, surpassing greater than 90% inhibiti...
Gainers: Blue Water Vaccines ( BWV ) +108% . Hill International ( HIL ) +61% . Eargo ( EAR ) +58% . JE Cleantech Holdings ( JCSE ) +44% . Cassava Sciences ( SAVA ) +30% . Laird Superfood ( LSF ) +19% . LexinFintec...
Biomea Fusion press release ( NASDAQ: BMEA ): Q2 GAAP EPS of -$0.59 beats by $0.01 . Cash position of $150.2 million at the end of the second quarter of 2022. For further details see: Biomea Fusion GAAP EPS of -$0.59 beats by $0.01
Continued to make significant progress advancing BMF-219, the company’s lead investigational orally administered covalent menin inhibitor, in multiple oncology indications COVALENT-101 (Phase I) study is enrolling for patients with Acute Lymphoblastic Leukemia (ALL), Acute Myel...
Biomea to present two oral abstracts across multiple animal models highlighting the ability of BMF-219, a covalent menin inhibitor, to significantly lower HbA1C (approximately two-fold greater reduction than active control, liraglutide) and to increase beta cell function. BMF-219 show...
A new 2022/23 study continues the trading studies from 2017 testing abnormal Russell Index reconstitution returns from scholarly literature. Since 2017 the best return results from a price momentum test generated +57.90% in the first six months and average gains reached +29.04% in the...
Biomea Fusion Inc. (NGS:BMEA) is one of today's notable stocks on the rise, up 106.9% to $11.05. Over the past year, Biomea Fusion Inc. has traded in a range of $2.84 to $19.34 and is now at $11.05, 289% above that low. Receive IBN Spotlights - "Bite Size" Small, Mid and Large-Cap Tech...
Biomea Fusion Inc. (NGS:BMEA) is one of today's notable stocks on the rise, up 89.3% to $10.11. In the past 52 weeks, shares of Biomea Fusion Inc. have traded between a low of $2.84 and a high of $20.24 and is now at $10.11, which is 256% above that low price. Receive IBN Spotlights - ...
Biomea Fusion (NASDAQ:BMEA) said on Wednesday the first patient had been dosed in the Phase I study evaluating BMF-219 in multiple myeloma cohort of the trial. (BMEA) stock rose 5%. The company will test the drug in patients with acute myeloid leukemia, acute lymphocytic leukem...
News, Short Squeeze, Breakout and More Instantly...
2024-07-18 02:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-18 04:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, NY / ACCESSWIRE / June 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biomea Fusion, Inc. ("Biomea" or "the Company") (NASDAQ:BMEA). Investors who purchased Biomea securities are encouraged to obtain additional information...